Literature DB >> 10501918

Glutamyl hydrolase and the multitargeted antifolate LY231514.

M S Rhee1, T J Ryan, J Galivan.   

Abstract

PURPOSE: To examine the activity of glutamyl hydrolase (GH) on the poly-gamma-glutamates of multitargeted antifolate (MTA) (LY231514) and the effect of enhanced GH on the pharmacological activity of MTA.
METHODS: Expressed and purified GH were used to study the enzymatic cleavage of MTA poly-gamma-glutamates and wild-type and GH-enhanced H35 hepatoma cell lines to evaluate growth inhibition.
RESULTS: MTA tri- and penta-gamma-glutamates were good substrates for human GH, having higher rates than MTX tri- and penta-gamma-glutamates. Preferential hydrolysis with human enzyme occurred at the two gamma-glutamyl bonds at the carboxyl end of the molecule, whereas the rat enzyme preferred the innermost gamma-linkage. Incubation of rat H35 hepatoma cell lines with MTA resulted in the intracellular accumulation of primarily tetra-, penta-, and hexa-gamma-glutamate. The formation of these were markedly reduced in H35D cells, which is a line resistant to antifolates chiefly through enhanced cellular levels of GH activity.
CONCLUSIONS: MTA poly-gamma-glutamates are effective substrates for GH and their pharmacological effectiveness bears an inverse relationship to cellular GH activity. This observation, along with enhanced resistance to MTA of thymidylate synthase-amplified cells, substantiates the importance of the poly-gamma-glutamates of MTA inhibiting TS as the primary target. Further evidence for the inverse relationship of GH to classical antifolate pharmacological activity is established.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10501918     DOI: 10.1007/s002800051000

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  7 in total

1.  Pretreatment Red Blood Cell Total Folate Concentration Is Associated With Response to Pemetrexed in Stage IV Nonsquamous Non-Small-cell Lung Cancer.

Authors:  Stephen J Bagley; Steven Vitale; Suhong Zhang; Charu Aggarwal; Tracey L Evans; Evan W Alley; Roger B Cohen; Corey J Langer; Ian A Blair; Anil Vachani; Alexander S Whitehead
Journal:  Clin Lung Cancer       Date:  2016-10-26       Impact factor: 4.785

2.  γ-Glutamyl hydrolase modulation significantly influences global and gene-specific DNA methylation and gene expression in human colon and breast cancer cells.

Authors:  Sung-Eun Kim; Toshinori Hinoue; Michael S Kim; Kyoung-Jin Sohn; Robert C Cho; Peter D Cole; Daniel J Weisenberger; Peter W Laird; Young-In Kim
Journal:  Genes Nutr       Date:  2014-12-13       Impact factor: 5.523

3.  A phase II study of pemetrexed in patients with advanced hepatocellular carcinoma.

Authors:  Allen L Cohn; J William Myers; Steven Mamus; Charles Deur; Steven Nicol; Karen Hood; Muhammad M Khan; Des Ilegbodu; Lina Asmar
Journal:  Invest New Drugs       Date:  2008-02-28       Impact factor: 3.850

4.  Cancer chemotherapy: targeting folic acid synthesis.

Authors:  Nicole Hagner; Markus Joerger
Journal:  Cancer Manag Res       Date:  2010-11-19       Impact factor: 3.989

5.  Novel drug-resistance mechanisms of pemetrexed-treated non-small cell lung cancer.

Authors:  Ryosuke Tanino; Yukari Tsubata; Nanae Harashima; Mamoru Harada; Takeshi Isobe
Journal:  Oncotarget       Date:  2018-03-30

6.  Tailoring treatment of nonsmall cell lung cancer by tissue type: role of pemetrexed.

Authors:  Steven F Powell; Arkadiusz Z Dudek
Journal:  Pharmgenomics Pers Med       Date:  2009-06-24

7.  Cisplatin-resistant A549 non-small cell lung cancer cells can be identified by increased mitochondrial mass and are sensitive to pemetrexed treatment.

Authors:  Yanyun Gao; Patrick Dorn; Shengchen Liu; Haibin Deng; Sean R R Hall; Ren-Wang Peng; Ralph A Schmid; Thomas M Marti
Journal:  Cancer Cell Int       Date:  2019-11-29       Impact factor: 5.722

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.